|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 1994年中国糖尿病患病率及其危险因素显示文摘为调查全国糖尿病及糖耐量低减(IGT)的患病率及糖尿病危险因素,对全国19省市年龄≥25岁的224251人群进行横向普查,根据1985年WHO标准,年龄在25~64岁的213515人群中,糖尿病患病率为2.51%,糖耐量低减患病率为3.20%(按1990年全国人口年龄标化后患病率);新诊断糖尿病的比例(70.33%)明显高于已确诊的糖尿病者。现患病率是10年前的3.0倍左右,其中农村患病率的增长高于城市。经多因素logistic逐步回归分析显示,年龄、体重指数或腰臀围比、糖尿病家族史、高血压、低体力活动、高收入为非胰岛素依赖型糖尿病(NIDDM)的独立危险因素,而且在高收入人群中,低文化程度也为NIDDM的独立危险因素。 | Pan Xiaoren *, Yang Wenying, Liu Juan, et al. *Department of Endocrinology, China Japan Friendship Hospital, Beijing 100029 | 1997 | 中华内科杂志1997，36，6： | 415 |
| 2 | Glutamine synthetase as an early marker for hepatocellular carcinoma based on proteomic analysis of resected smal hepatocel ular carcinomas显示文摘BACKGROUND:Hepatocellular carcinoma(HCC)is a highly malignant tumor with a poor prognosis.Because small HCCs possess most of the characteristics of early HCC,we investigated small HCCs to screen potential biomarkers for early diagnosis.METHODS:Proteins were extracted from 10 sets of paired tissue samples from HBV-infected small-HCC patients.The extracted proteins were well resolved by two-dimensional electrophoresis.These HCC-associated proteins were then identified by MALDI-TOF/TOF MS following image analysis.Western blotting and immunohistochemistry were used to assess glutamine synthetase(GS)and phenazine biosynthesislike domain-containing protein(PBLD)expression in liver tissue.Enzyme-linked immunosorbent assays in 152 serum samples(from 49 healthy donors,24 patients with liver cirrhosis,and 79 with HCC)were used to further assess the significance of GS clinically.RESULTS:Fifteen up-regulated and three down-regulated proteins were identified.Western blotting confirmed GS overexpression and decreased PBLD expression in liver tissue.Immunohistochemistry showed that GS was expressed in 70.0%(84/120)of HCCs and 35.8%(43/120)of nontumor tissues;PBLD was expressed in 74.2%(89/120) of nontumor tissues and 40.8%(49/120)of HCCs.The Chi-square test showed significant expression differences between HCCs and adjacent tissues.Consistent with this,serum GS levels in HCC patients were significantly higher than those in liver cirrhosis patients and healthy donors,while the latter two groups were also significantly different.In addition, a diagnostic cutoff value of 2.6 mg/ml was used for GS;it was elevated in 19(76.0%)of 25 HCC patients with AFP≤20 ng/ml and 47(88.7%)of 53 HCC patients with AFP≤200 ng/ml.CONCLUSION:GS and PBLD are abnormally expressed in most HCCs.GS may be a novel serum marker for early HCC, especially for those patients with low AFP levels(≤200 ng/ml). | Jiang Long,Zhen-Wei Lang,Hua-Guang Wang,Tai-Ling Wang,Bao-En Wang and Si-Qi Liu Liver Research Center,Beijing Friendship Hospital, Capital Medical University,Beijing 100050,China Department of Hepatology,Department of Pathology, Beijing Youan Hospital,Capital Medical University,Beijing 100069,China Department of Pharmaceutical Affairs,Beijing Chaoyang Hospital,Capital Medical University,Beijing 100020,China Department of Pathology,China-Japan Friendship Hospital,Beijing 100029,China Beijing Genomics Institute,Chinese Academy of Science,Beijing Airport Industrial Zone B-6,Shunyi,Beijing 101300,China | 2010 | Hepatobiliary & Pancreatic Diseases International2010，9，3： | 21 |
| 3 | Clinical and endoscopic features of Chinese reflux esophagitis patients显示文摘AIM: To analyze the clinical and endoscopic features of Chinese patients with reflux esophagitis (RE). METHODS: A total of 1405 RE patients were analyzed retrospectively. Data on gender, age, presence/absence of H pylori infection and associated esophageal hiatal hernia were collected. Esophagitis was divided into different grades according to Los Angeles Classification. RESULTS: Of 18823 patients, 1405 were diagnosed as RE. The ratio of male to female patients was 1.75:1 (P < 0.01). The mean age of male and female patients was significantly different (P = 0.01). The peak age at onset of the disease was 40-60 years. According to Los Angeles Classification, there were significant differences in the age of patients with grades A and B compared to patients with grades C and D (P < 0.01). Two hundred and seventy-seven patients were infected with H pylori, the infection rate was low (P < 0.01). Complication of esophageal hiatal hernia was found to be significantly associated with the severity of esophagitis and age in 195 patients (P < 0.01). Esophageal mucosa damages were mainly located at the right esophageal wall. CONCLUSION: The peak age of onset of RE is 40-60 years and higher in males than in females. The mean age of onset of RE is lower in males than in females. The infection rate of H pylori is significantly decreased in patients with esophagitis. Old age and esophageal hiatal hernia are associated with more severe esophagitis. Right esophageal mucosal damage can occur more often in RE patients. | Wei Li, Shu-Tian Zhang, Zhong-Lin Yu, Department of Gastroenterology, Beijing Friendship Hospital Affiliated to Capital Medical University Faculty of Gastroenterology, Capital Medical University Beijing Digestive Disease Center, Beijing 100050, China | 2008 | World Journal of Gastroenterology2008，14，12： | 12 |
| 4 | A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B显示文摘BACKGROUND: Lamivudine was approved for the treat- ment of chronic hepatitis B in China in 1999; however the long-term result has not yet been reported in detail. This clinical trial was to evaluate the long-term efficacy and safe- ty of 3-year lamivudine treatment for chronic hepatitis B and the impact of emergence of YMDD mutation of hepa- titis B virus (HBV). METHODS: This multi-center, randomized, double-blind, placebo controlled trial began from 1996 to 1999. A total of 429 patients with serum HBsAg, HBeAg and HBV DNA positive were randomized to receive either lamivudine 100 mg daily (322 patients) or placebo (107) for the first 12 weeks. All patients were given subsequently open labelled lamivudine 100 mg/d for a total of 156 weeks. RESULTS: After 12-week lamivudine therapy, the levels of serum HBV DNA decreased rapidly. The negativity of HBV DNA (<1.6 pg/ml) at week 12 was 92.2% in the lamivudine group, whereas it was only 14.1% in the place- bo group (P<0.01). After 1-year lamivudine treatment, 72.7% of the patients showed undetectable serum HBV DNA (<1.6 pg/ml). At the end of 3 years, serum HBV DNA continued to be substantially suppressed with a me- dian level below a detectable level in patients with non-YM- DD variant HBV, which was increased to 86 mEq/ml (bD- NA method, equivalent hybridization method 10 pg/ml) in patients with YMDD mutation. At the end of 1, 2 and 3 years, the rates of HBeAg loss were 9.5%, 16.8% and 20.0% respectively and the rates of HBeAg/anti-HBe sero- conversion were 8.3%, 11.5% and 17.3%. The rates of HBeAg loss and seroconversion were correlated with the baseline level of ALT. In patients with a baseline level of alanine transaminase (ALT)>2 × upper limit of normal (ULN) and ALT >5×ULN, the rates of HBeAg loss were 42.2% and 66.7%, and the rates of seroconversion were34.4% and 61.1% respectively (P<0.01) at the end of year 3. The levels of ALT at year 3 remained normal in 58.8% of patients whose baseline level of ALT was elevated, and in 79.1% of patients whose level of ALT was normal before treatment. YMDD mutations occurred in 12.1%, 49.7% and 70.5% of patients respectively at year 1, 2 and 3. In pa- tients with YMDD mutation, the levels of HBV DNA were increased slightly with mild to moderate elevation of ALT level. HBeAg loss and seroconversion were 20.0% and 15.1% in patients with YMDD mutation at the end of year 3, which were lower than those in non-variant patients (P<0.01). Adverse drug reactions or events varied gene- rally from mild to moderate. In 2 patients serious adverse events (fatigue and abdominal distension) were related to medication. ALT flares (ALT>5×ULN) occurred in 17 patients: 10 were YMDD mutants and 7 were non-mutants; all of them were relieved. No death occurred in the period of 3 years. CONCLUSION: Sustained inhibition of HBV replication and clinical improvement could be obtained after 3-year lamivudine therapy of good tolerance and safety. | Guang-Bi Yao, Zhen-Yu Cui, Bao-En Wang, Ji-Lu Yao and Min-De Zeng Shanghai, China Shanghai Jing-An Qu Central Hospital, Shanghai 200040, China Beijing Ditan Hospital, Beijing 100011 , China Beijing Friendship Hospital, Beijing 100050, China 3rd Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510630, Chinaand Shanghai Renji Hospital, Shanghai Second Medical University, Shanghai 200001 , China | 2004 | Hepatobiliary & Pancreatic Diseases International2004，3，2： | 11 |
| 5 | Lamivudine treatment of decompensated hepatitis B virus-related cirrhosis显示文摘BACKGROUND: Patients with decompensated hepatitis B vires (HBV)-related cirrhosis tend to have low or undetectable HBV replication. However, some patients continue to have high levels of HBV replication and effective suppression of HBV replication with antiviral agents may potentially decrease hepatic necroinflammation and improve or stabilize liver function. This review was to under stand the efficacy and safety of lamivudine in the treatment of decompensated HBV cirrhosis. DATA SOURCES: An English-language literature search (MEDLINE January 1988-July 2005) was performed, and a total of 52 articles/abstracts relevant to the issue were selected. After review of the selected papers, the meaningful results and conclusions were extracted using scientific crite ria. The papers reviewed pertained mainly to the efficacy and safety profiles of lamivudine treatment for decompensated HBV cirrhosis. RESULTS: The ultimate treatment of decompensated HBV cirrhosis is liver transplantation, but lamivudine treatment may lead to rapid suppression of viral replication and improvement of biochemical and clinical parameters, reduced morbidity and hospitalization for complications of liver disease, increased pre-transplant survival as well as reduced need for transplantation. However, viral resistance can develop after prolonged treatment with lamivudine, and breakthrough hepatitis may be fatal in few patients. Adefovir is effective for lamivudine-resistant HBV mutants. CONCLUSIONS: Antiviral therapy with lamivudine for decompensated HBV cirrhosis can be effective. However, some patients may experience a hepatitis flare with the emergence of YMDD mutants resulting in progressive worsening of liver disease, and should be referred for 'rescue' therapy with other nucleoside/nucleotide analogues such as adefovir dipivoxil. | Fu-Kui Zhang Liver Research Center, Beijing Friendship Hospital, Capital University of Medical Sciences, Beijing 100050, China | 2006 | Hepatobiliary & Pancreatic Diseases International2006，5，1： | 10 |
| 6 | Early changes of hepatic hemodynamics measured by functional CT perfusion in a rabbit model of liver tumor显示文摘BACKGROUND:Early detection and treatment of hepatocellular carcinoma is crucial to improving the patients' survival.The hemodynamic changes caused by tumors can be serially measured using CT perfusion.In this study,we used a CT perfusion technique to demonstrate the changes of hepatic hemodynamics in early tumor growth,as a proof-of-concept study for human early hepatocellular carcinoma.METHODS:VX2 tumors were implanted in the liver of ten New Zealand rabbits.CT perfusion scans were made 1 week(early) and 2 weeks(late) after tumor implantation.Ten normal rabbits served as controls.CT perfusion parameters were obtained at the tumor rim,normal tissue surrounding the tumor,and control liver;the parameters were hepatic blood flow,hepatic blood volume,mean transit time,permeability of capillary vessel surface,hepatic arterial index,hepatic arterial perfusion and hepatic portal perfusion.Microvessel density and vascular endothelial growth factor were correlated.RESULTS:At the tumor rim,compared to the controls,hepatic blood flow,hepatic blood volume,permeability of capillary vessel surface,hepatic arterial index,and hepatic arterial perfusion increased,while mean transit time and hepatic portal perfusion decreased on both early and late scans(P<0.05).Hepatic arterial index increased(135%,P<0.05),combined with a sharp increase in hepatic arterial perfusion(182%,P<0.05) and a marked decrease in hepatic portal perfusion(-76%,P<0.05) at 2 weeks rather than at 1 week(P<0.05).Microvessel density and vascular endothelial growth factor showed significant linear correlations with hepatic blood flow,permeability of capillary vessel surface and hepatic arterial index,but not with hepatic blood volume or mean transit time.CONCLUSION:The CT perfusion technique demonstrated early changes of hepatic hemodynamics in this tumor model as proof-of-concept for early hepatocellular carcinoma detection in humans. | Guo-Lin Ma,Rong-Jie Bai,Hui-Jie Jiang,Xue-Jia Hao,Xu-Peng Dong,Da-Qing Li,Xin-Ding Liu and Lai Wei Department of Radiology,China-Japan Friendship Hospital,Beijing 100029,China Department of Radiology,Beijing Jishuitan Hospital,Beijing 100035,China Department of Radiology,Second Affiliated Hospital,Harbin Medical University,Harbin 150086,China | 2012 | Hepatobiliary & Pancreatic Diseases International2012，11，4： | 8 |
| 7 | Transretinoic acid inhibits rats gastric epithelial dysplasia induced by N-methyi-N-nitro-N-nitrosoguanidine:influences on cell apoptosis and expression of its regulatory genes显示文摘INTRODUCTIONGastric epithelial dysplasia (GED) hypothetically is a straight-forward concept: dysplastic epithelium replacing the normal gastric epithelium of the stomach [1].In the stomach ,like any other segment of the gut ,it is defined as an unequivocal non-invasive epithelial change[2,3].The observation of gastric dysplasia as a cancerous lesion was recognized over a century ago ,but it is only after the advent of gastroscopy that its clinical significance has been stressed[4-7]. | Ru Tao Cui~1 Gan Cai~2 Zhao Bao Yin~(2*) Yong Cheng~2 Qiu Hong Yang~1 Tao Tian~(3#) ~1Liver Center,Beijing Friendship Hospital Affiliated to CapitalUniversity of Medical Sciences~2Department of Gastroenterology,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai China and Department of Pathophysiology.Shanghai Medical University.Shanghai,China ~3Pathological Department,Shanghai Medical University (?)Now working at UCLA,USA ~#Now working at University of Michigan,USADr.Ru Tao Cui graduated and got the bachelor degree from Shandong University of Traditional Chinese Medicine in 1994,got doctor degree from Shanghai University of Traditional Chinese Medicine in 2000,now studying as a postdoc,majoring gastroenterology,having 29 papers published. | 2001 | World Journal of Gastroenterology2001，7，3： | 8 |
| 8 | Clinical evaluation of serum antimitochondrial antibody-negative primary biliary cirrhosis显示文摘BACKGROUND: Primary biliary cirrhosis (PBC) is cha- racterized by frequent presence of antimitochondrial anti- bodies (AMAs). The sensitivity and specificity of AMA for PBC are both greater than 90%-95%, so the presence of AMA in serum is the major hallmark in PBC. However, it has long been recognized that in 5%-10% of patients the clinical, biochemical and histological features are diagnos- tic for PBC, but their sera are consistently tested negative for AMA/AMA-M2. This study aimed to evaluate whether the presence of AMA alters the clinical, serological and his- tological features of the disease. METHODS: Clinical data of 70 patients clinically and/or histologically diagnosed with PBC were reviewed. AMA- negative and AMA-positive patients were compared in terms of clinical, biochemical, immunological and histo- logical features. RESULTS: At presentation, 11 patients were serum AMA/ AMA-M2 negative. At the initial visit, AMA-negative and AMA-positive patients were similar in terms of age, sex, clinical manifestations, liver biochemistries and histological findings. The mean level of serum immunoglobulin M (IgM) was significantly lower in AMA-negative PBC pa- tients than in AMA-positive PBC patients (2851±1418 mg/L vs 6361 ±4928 mg/L, P =0.033). Serum antinuclear anti- bodies ( ANA) and/or smooth muscle antibodies ( SMA) were more frequently positive in the AMA-negative PBC patients than in the AMA-positive patients (81.8% vs 40.7%, P =0.031). CONCLUSION: AMA-negative PBC patients are characte- rized by relatively lower levels of serum IgM and a higher prevalence of serum ANA/SMA and are not associated with substantial differences in the clinical, biochemical and histo- logical spectrum of the disease. | Fu-Kui Zhang, Ji-Dong Jia and Bao-En Wang Beijing, China Liver Research Center, Beijing Friendship Hospital, Capital University of Medical Sciences, Beijing 100050 , China | 2004 | Hepatobiliary & Pancreatic Diseases International2004，3，2： | 7 |
| 9 | Surgical treatment of portal hypertension显示文摘Portal hypertension is a common disease with highmortality and serious influence on the life quality ofpatients. At present, shunt and disconnection arecommonly used for the treatment of portal hyperten-sion. In recent years, combined procedures of shuntand disconnection have evoked the potential interestof surgeons. Initial experimental studies and clinicalobservations showed that the combined proceduresare ideal for treating portal hypertension. Transju-gular intrahepatic portacaval shunt (TIPS) is a newminimally invasive technique in treating portal hy-pertension. Some surgeons have tried to perform dis-connection under laparoscopy with success. Livertransplantation will be the focus of portal hyperten-sion surgery in the future. | Yu Wang From the Department of General Surgery, Beijing Friendship Hospital, Capital University of Medical Sciences, Beijing 100050, China | 2002 | Hepatobiliary & Pancreatic Diseases International2002，1，2： | 6 |
| 10 | Protective effect of liver ischemic preconditioning on rat hepatocytes显示文摘Ischemic preconditioning (IPC) protects liver graft function following ischemia in liver transplantation and liver resection. The aim of this study was to assess the advantages and any potential disadvantages of liver IPC prior to isolation for rat hepatocytes during isolation and cryopreservation. After isolating and thawing the cryopreserved hepatocytes after 14 and 28 d,cell viability,efficiency,and lactate dehydrogenase (LDH) levels in preserve solution were examined for every group. Groups treated with IPC had better cell viability determination,assessment of plating efficiency and lactate dehydrogenase (LDH) assay than Group without IPC,suggesting that IPC prior to isolation may have a significant protective effect on hepatocytes subjected to isolation and short period cryopreservation. | FU JianZhu1,2,WANG Yu1,ZHANG LiJun2 & YU ZeLi2 1 Department of General Surgery,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China 2 Department of General Surgery,Beijing Tongren Hospital,Capital Medical University,Beijing 100730,China | 2009 | Science China(Life Sciences)2009，52，9： | 3 |
| 11 | Numerical Solution of Constrained Mechanical System Motions Equations and Inverse Problems of Dynamics显示文摘In this paper the method of design of kinematical and dynamical equations of mechanical systems, applied to numerical ealization, is proposed. The corresponding difference equations, which are obtained, give a guarantee of computations with a given precision. The equations of programmed constraints and those of constraint perturbations are defined. The stability of the programmed manifold for numerical solutions of the kinematical and dynamical equations is obtained by corresponding construction of the constraint perturbation equations. The dynamical equations of system with programmed constraints are set up in the form of Lagrange’s equations in generalized coordinates. Certain inverse problems of rigid body dynamics are examined. | R.G. Muharliamov (Russian Peoples’ Friendship University, 117198, Moscow, Mikluho Maklaya,6,Russia.) | 2001 | 应用数学2001，14，2： | 2 |
| 12 | Impact of virus genotype on interferon treatment of patients with chronic hepatitis C: a multicenter controlled study显示文摘BACKGROUND: Some factors have been reported to besassociated with a greater likelihood of sustained viral re-sponse ( SVR) in the interferon (IFN) treatment of chronichepatitis C. The factors include HCV genotype, HCVRNA level in serum, state of liver disease, baseline bodyweight, age, sex, and race. The aim of this trial was to in-vestigate the influence of HCV genotype on the IFN treat-ment of patients with chronic hepatitis C.METHODS: The genotypes of HCV virus were determinedin the patients with chronic hepatitis C from several hospi-tals of China enrolled into the randomized, opened andcontrolled trial of Peg-IFN alpha-2a (pegasys) treatment,controlled with IFN-α-2a (roferon-A). The serum ALTlevels and HCV RNA concentrations of the patients weredetected before and at the end of treatment and during thefollow-up. The influence of HCV genotype on the IFNtreatment of patients with chronic hepatitis C was analyzedin intention-to-treat (ITT) population.RESULTS: The HCV genotypes of 202 patients were deter-mined. Of these patients, 158(78.22%) were infected withgenotype 1 HCV and 44(21.78%) with genotype non-1.The viral response at the end of treatment (ETVR) andsustained viral response (SVR) rates were 53.80% and25.32% respectively in patients with genotype 1 HCV, butthey were 61.36% and 43.18% in patients with genotypenon-1. The difference of SVR between patients with geno-type 1 HCV and those with genotype non-1 was significant(P =0.021). After being grouped by the used drugs, theETVR rates of patients infected with genotype 1 and non-1HCV were 76.83% and 80.95% in the patients treated withpegasys (P =0.686); but their SVR rates were 35.37% and66.67% (P =0. 01). The viral relapse rate of genotype 1HCV (55.56%) was significantly higher than that of geno-type non-1 HCV (23.53%) (P=0.02). In roferon-A group,the ETVR and SVR rates of patients with genotype 1 HCVwere 28.95% and 14.47% respectively, which were lowerbut not more significant than those of patients with geno-type non-1 HCV (43.48% and 21.74%). Moreover, the vi-ral relapse rate of genotype 1 HCV (72.73%) was higherbut not more significant than that of genotype non-1 HCV(50.00%) (P=0.21).CONCLUSION: HCV genotype could affect the efficacies,mainly sustained responses, of IFN treatment in patientswith chronic hepatitis C, and the effects of IFN are relatedto drugs and therapeutic course. | Yao Xie, Dao-Zhen Xu, Zhi-Meng Lu, Kang-Xian Luo, Ji-Dong Jia, Yu-Ming Wang,Gui-Zhen Zhao, Shu-Lin Zhang and Da-Zhi Zhang Department of Infeetious Diseases , Beijing Ditan Hos-pital, Beijing 100011 , China Department of Infec-tious Diseases, Ruijin Hospital, Shanghai 200025, China De-partment of Infectious Diseases, Naifang Hospital, First Military Medical U-niversity, Guangzhou 510515, China (Luo KX) Center of Liver Disease,Beijing Friendship Hospital, Beijing 100050, China (Jia J D ) Institute ofInfectious Disease, Southwest Hospital, Third Military Medical University,Chongqing 410032, China Department of Infectious Disea-ses, Second Hospital, China Medical University, Shenyang 110004, China Department of Infectious Diseases, First Hospital, Xi’ an Jiao-tong University, Xi’ an 710061 , China ) Liver Disease Centerof Chongqing, Second Hospital, Chongqing Medical University,Chongqing 410010, China | 2004 | Hepatobiliary & Pancreatic Diseases International2004，3，3： | 2 |
| 13 | 提升上海对外交流影响力 促进现代化国际大都市建设的建议显示文摘上海是我国重要的对外开放城市,长期以来,和其他城市相比,上海在发挥对外交流影响力方面,具有很强的比较优势.但毋庸讳言,进入新世纪以来,这种比较优势正在缩小;另一方面,新的历史时期要求上海有更强的对外交流影响力.因此上海实际上面临着双重挑战,需要认真思考如何进一步提升上海对外交流影响力,促进现代化国际大都市建设.根据上海市政协2013年重点工作安排,对外友好委员会组织了20多名委员,联合高校专家,围绕进一步提升上海对外交流影响力,促进现代化国际大都市建设开展调研,形成本报告. | Shanghai Municipal People’s Political Consultative Conference Committee of International Friendship | 2014 | 公共外交季刊2014，0，2： | 2 |
| 14 | Professor Zhou Jin-huang,a pioneer in the pharmacologyintegrating traditional Chinese medicineand western medicine显示文摘Professor Zhou was born in 1909 when the lastdriperial dynasty, Qing dynasty, went near its end andmodern sciences including medical sciences began totake root in China. Modern schools and universitieswere established to substitute the old private tutoringsystem in which only one teacher was needed to handlea group of young pupils of different ages. Zhou re-ceived both types of education and was finally | LIU Gan-zhong( Professor of Pharmacology,Dept Materia Medico and Pharmacology,China-Japan Friendship Hospital) | 1989 | 中国药理学与毒理学杂志1989，3，3： | 2 |
| 15 | 友好城市:谱写民间外交事业新篇章显示文摘在我国,国际友好城市(以下简称“友城”)是指我国省、自治区、直辖市及其所辖城市与外国省(州、县、大区、道等)、城市之间建立的联谊与合作关系。 | China International Friendship Cities Association | 2016 | 重庆与世界2016，0，41： | 2 |
| 16 | CT Scanning For the Evaluation of Cervical Spine Trauma.显示文摘Thirty-three cases of cervical spine fractures were inenti-fied among 51 cases undergoing GT of the cervical spine fol- | Zeng Youlu et al. Dept Radiology China-Japan Friendship Hospital. Beijing 100029. Chin J Orth | 1995 | Chinese Medical Journal1995，，11： | 2 |
| 17 | Prevalence of le- sions of the pars oesophageal region of the stomach of sows at slaughter 显示文摘 | O'Sullivan T Friendship R M Ball R O | 1996 | In Proc Am Assoc Swine Practitioners1996，，： | 1 |
| 18 | ALTERNATIVES TO ANTIBIOTIC USE: PROBIOTICS FOR THE GUT显示文摘 | Gregor Reid Robert Friendship | 2002 | Animal Biotechnology2002，，1： | 1 |
| 19 | Manage-ment factors associated with farrowing rate in commercial sowherds in Ontario显示文摘 | Beth Young Catherine E Dewey Robert M Friendship | 2010 | Can Yet J2010，，51： | 1 |
| 20 | Combined electro-acupuncture with liver artery intubation in treatment of massive liver cancer显示文摘Objective: To investigate the clinical effectiveness ofelectro-acupuncture therapy (EAT) in combinationwith liver artery intubation chemotherapy for mas-sive liver cancer.Methods: A total of 106 patients were divided into 3groups. In group A, patients underwent EAT incombination with invasive therapy. In group B, pa-tients received EAT alone, in group C, patients un-derwent liver artery intubation chemotherapy. Ingroup A and B, subcostal oblique incision was per-formed to expose liver cancer, and electrodes wereinserted into the tumor under direct vision. In groupA, liver artery intubation was performed during ope-ration, followed by chemotherapy through the tube.Liver artery intubation chemotherapy was performedonly in group C.Results: The effective rate was 73.7% (28/38),55.6% (20/36) and 28.1% (9/32) in group A, Band C, respectively.Conclusions: Electro-acupuncture therapy in combi-nation with liver artery intubation chemotherapy a-chieves best results, It is an effective therapy formassive liver cancer. | Yu-Ling Xin De-Ruo Liu Xin Meng the Department of Thortacic Surgery, China-Japan Friendship, Hospital, Beijing 100029, China | 2002 | Hepatobiliary & Pancreatic Diseases International2002，1，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员